Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion, Nanosphere, Cepheid Lead Stock Risers in May GWDN Index

NEW YORK (GenomeWeb News) – Shares of Vermillion, Nanosphere, and Cepheid were the top gainers in May among the 36 companies that comprise the GenomeWeb Daily News Index.
 
Shares of Vermillion, which had the sharpest increase, rose 92.6 percent for the month. However, the stock has fallen steadily since reaching a high of $5.14 on May 6, three trading days after closing at $1.16 to start the month.
 
Vermillion, which reported in mid-May that it had cut its first-quarter net loss by 20 percent, said that it expects to file its ovarian tumor triage test, called OVA1, with the US Food and Drug Administration within the next couple of months.
 
Nanosphere’s stock has risen throughout the month, with an uptick after its first-quarter results were released on May 13. The firm reported that its Q1 revenues more than doubled year over year on initial customer adoption of its Verigene system. Its shares climbed 44.1 percent for the month of May.
 
Cepheid was the other firm in the Index whose shares gained more than 30 percent for the month, rising 34.5 percent. The firm started the month by reporting that its first-quarter revenues had increased 76 percent year over year along with a sharp drop in its net loss. It also inked a couple of group purchasing deals during the month for its GeneXpert molecular diagnostic system and associated assays.
 
On the other end of the spectrum, two firms — DeCode Genetics and Helicos BioSciences —saw their shares drop more than 20 percent for the month of May.
 
DeCode started the month by reporting a 74.4 percent increase in Q1 revenues, but its shares slipped over the last half of the month and closed down 24.7 percent.
 
Helicos, whose shares fell 21.2 percent during May, reported its first-quarter results at the end of April. During that quarter, it shipped its first Helicos Genetic Analysis System to genomics services firm Expression Analysis. Since then, it has yet to announce another sale or shipment of its system.
 
Overall, the Index gained 3.1 percent for the month of May, matching the increase for the Dow Jones Industrial Average. In comparison, the Nasdaq jumped 10.7 percent, and the Nasdaq Biotech Index rose 4.7 percent form the month.
 
In addition, molecular diagnostics firm Gen-Probe has replaced Lumera in the GWDN Index as of May 1.
 
While GenomeWeb Daily News covers many more firms than are in the Index, those that have been included have a significant portion of their business focused on molecular biology and cellular research tools and are publicly traded in the US.

 
GenomeWeb Daily News Index
Company
Ticker
Current Price
(May 30, 2008)
Last
Price
(April 30, 2008)
% change
Accelrys
ACCL
6.52 5.67
14.99
Accelr8
AXK
4.62 3.99
15.79
Affymetrix
AFFX
12.06 10.91
10.54
Agilent
A
37.39 30.21
23.77
Applied Biosystems
ABI
34.76 31.91
8.93
Beckman
BEC
69.39 68.30
1.60
Becton Dickinson
BDX
84.45 89.40
-5.54
Bio-Rad
BIO
89.48 83.35
7.35
Bruker
BRKR
11.64 12.12
-3.96
Caliper
CALP
3.58 3.65
-1.92
Celera
CRA
12.88 13.38
-3.74
Cepheid
CPHD
26.32 19.57
34.49
Clinical Data
CLDA
19.12 15.42
23.99
CombiMatrix
CBMX
9.54 11.10
-14.05
Compugen
CGEN
2.03 2.30
-11.74
DeCode Genetics
DCGN
1.16 1.54
-24.68
Genomic Health
GHDX
17.30 21.52
-19.61
Gen-Probe*
GPRO
56.94 56.36
1.03
Helicos BioSciences
HLCS
4.69 5.95
-21.18
Illumina
ILMN
78.48 77.89
0.76
Invitrogen**
IVGN
45.96 46.79 -1.77
Luminex
LMNX
22.24 19.51 13.99
MDS
MDZ
18.71 19.91 -6.03
Millipore
MIL
72.65 70.10 3.64
Nanogen
NGEN
0.33 0.41 -19.51
Nanosphere
NSPH
9.60 6.66 44.14
Orchid Cellmark
ORCH
2.83 2.56 10.55
PerkinElmer
PKI
28.28 26.56 6.48
Qiagen
QGEN
19.91 22.21 -10.36
Rosetta Genomics
ROSG
4.16 4.89 -14.93
Sequenom
SQNM
7.69 6.32 21.68
Sigma-Aldrich
SIAL
58.76 57.02 3.05
Thermo
TMO
59.02 57.87 1.99
Third Wave
TWTI
10.61 8.82 20.29
Vermillion
VRML
2.08 1.08 92.59
Waters
WAT
61.52 61.46 0.10
GWDN Index Average 27.96
27.13
3.07

** Gen-Probe has replaced Lumera in the GWDN Index.
** Invitrogen’s April 30 closing price was actually $93.57. The price listed in the Index reflects a two-for-one stock split that took place on May 28.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.